AnaSpec Introduces Anti-MOG (1-125), Mouse Monoclonal
Being the first in the industry to provide a whole suite of reagents and assay kits for the advancement of MS research, AnaSpec is pleased to announce the release of the mouse monoclonal Anti-MOG (1-125).
- (1888PressRelease) November 19, 2010 - Fremont, CA - Anti-MOG monoclonal antibody was produced by immunizing Balb/c mice with recombinant MOG (1-125) as antigen. It is supplied as purified mouse IgG1, 250 ml in 40 mM MOPS (pH 7.5) with 50% glycerol containing 0.1% sodium azide and 0.1% BSA.
Myelin Oligodendrocyte Glycoprotein (MOG) is a member of the immunoglobulin superfamily and is expressed exclusively in the central nervous system (CNS). MOG protein constitutes only 0.01-0.5% of the CNS myelin proteins, has a mass of 27kDa, and is located in the outermost layer of myelin sheath (1-6). Mouse MOG is able to induce autoantibody production and relapsing-remitting neurological disease causing extensive plaque-like demyelination (1-4). Autoantibody response to mouse MOG has been observed in induced experimental autoimmune encephalomyelitis (EAE) in C57/BL6, 129/Sv, B6, and SJL mice (3-4).
AnaSpec has offered other MS research products, including MOG proteins, peptides, antibodies and assay kits.
The MOG proteins, with sequences corresponding to human, mouse and rat extracellular domain, together with a 6x His tag were expressed in E. coli and purified from urea denatured bacterial lysate. The molecular weight found in all 3 recombinant proteins was 14.23 kDa. These proteins were shown to induce EAE in either mouse (for the human and mouse rMOGs) or rat (for rat rMOG).
AnaSpec's MOG (35-55) peptide from mouse and rat sequence was shown to induce anti-MOG (35-55) autoantibody production in C57BL/6 mice at 100% incidence (10/10); providing quantitative data that this peptide is suitable for in vivo anti-MOG (35-55) autoantibody study. A cysteine-containing MOG (35-55) peptide induced polyclonal anti-MOG (35-55) antibody production in rabbits with high specificity, high affinity, and high titer indicating its high purity, as well as suitability for use in peptide-coated ELISA and Western blot. This mouse/rat MOG (35-55) peptide was used as a coating peptide to develop the industry's first anti-MOG (35-55) ELISA kit for EAE study. The detection limit of the kit was determined to reach as low as 50 pg of anti-MOG (35-55) autoantibody in serum or cerebrospinal fluid. Lot to lot variability of the MOG (35-55) was found to be minimal.
As for MOG Polyclonal Antibodies, one rabbit polyclonal antibodies towards the MOG extracellular domain raised against the human recombinant protein and the other against the mouse recombinant protein. These Protein A affinity purified antibodies recognized a 27kDa band.
The SensoLyte Anti-Human MOG (1-125) IgG Quantitation ELISA Kit, SensoLyteŇ Anti-Mouse MOG (1-125) and SensoLyteŇ Anti-Rat MOG (1-125) IgG ELISA assay kits are for determining the amount of anti-human MOG (1-125), anti-mouse MOG (1-125) and anti-rat MOG (1-125) antibodies. The improved SensoLyteŽ Anti -MOG(35 - 55) IgG Quantitative ELISA Kit (mouse/rat) is optimized to detect anti-MOG (35-55) mouse/rat IgG. Using strips pre-coated with MOG (35-55) peptide and pre-blocked with BSA, the amount of anti-MOG IgG subtypes in serum or cerebrospinal fluid can be determined by ELISA and the absorbance read at 450 nm.
http://www.anaspec.com/products/promotions.asp?col=1&row=1
Reference:
1. Linares, D. et al. Prot. Expr. Purif. 34, 249 (2004).
2. Bettadapura, J. et al. J. Neurochem. 70, 1593 (1998).
3. Oliver, AR. et al J. Immunol. 171, 462 (2003).
4. Von Budingen, H-C. et al. J. Clin. Imm. 21, 155 (2001).
5. Lyons, J-A. et.al. Eur. J. Immunol. 29, 3432 (1999).
6. Von Budingen, H-C. et.al. Eur. J. Immunol. 34, 2072 (2003)
About AnaSpec
AnaSpec is a leading provider of integrated proteomics solutions to the world's largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.
AnaSpec recently joined forces with Eurogentec to provide an even broader spectrum of products and services to serve the worldwide life science community.
For more information visit www.anaspec.com
About Eurogentec
Eurogentec is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertize in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec's Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.
Eurogentec is a privately held company headquartered in Ličge, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.
For more information visit www.eurogentec.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam